CoreCivic Receives Termination Notice From U.S. Immigration and Customs Enforcement At South Texas Family Residential Center

Written by Customer Service on June 10, 2024. Posted in Public Companies.

BRENTWOOD, Tenn., June 10, 2024 (GLOBE NEWSWIRE) — CoreCivic, Inc. (NYSE: CXW) (“CoreCivic”) received notification today from U.S. Immigration and Customs Enforcement (“ICE”) that the agency intends to terminate an inter-governmental service agreement (“IGSA”) between CoreCivic and ICE for services at the South Texas Family Residential Center in Dilley, TX (the “Facility”) effective in 60 days, or on or about August 9, 2024. For the year ended December 31, 2023, and for the quarter ended March 31, 2024, total revenues at the Facility were $156.6 million and $39.3 million, respectively. Given that the notice of termination was received today and based on cost uncertainties associated with the closure, CoreCivic is suspending its financial guidance for 2024. However, we estimate the annualized financial impact...

Crinetics Pharmaceuticals Announces June 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Written by Customer Service on June 10, 2024. Posted in Public Companies.

SAN DIEGO, June 10, 2024 (GLOBE NEWSWIRE) — Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on June 10, 2024, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 158,000 shares of its common stock to nine new non-executive employees under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “2021 Inducement Plan”). The stock options were granted as inducements material to the employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4). The 2021 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Crinetics, or following a bona fide period of non-employment, as an inducement material to such individuals’...

Centurion Acquisition Corp. Announces Pricing of $250 Million Initial Public Offering

Written by Customer Service on June 10, 2024. Posted in Public Companies.

NEW YORK, June 10, 2024 (GLOBE NEWSWIRE) — Centurion Acquisition Corp. (the “Company”) today announced the pricing of its initial public offering of 25,000,000 units at a price of $10.00 per unit. The units will be listed on the Nasdaq Global Market (“Nasdaq”) and will trade under the ticker symbol “ALFUU” beginning on June 11, 2024. Each unit consists of one Class A ordinary share and one-half of one redeemable warrant, with each whole warrant exercisable to purchase one Class A ordinary share at a price of $11.50 per share. Only whole warrants will be exercisable. Once the securities comprising the units begin separate trading, the Class A ordinary shares and warrants are expected to be listed on Nasdaq under the symbols “ALF” and “ALFUW,” respectively. The offering is expected to close on June 12, 2024. Centurion Acquisition...

End of the BAPE Public Information Period

Written by Customer Service on June 10, 2024. Posted in Public Companies.

A Positive Exercise for Falco MONTRÉAL, June 10, 2024 (GLOBE NEWSWIRE) — Falco Resources Ltd. (TSX.V: FPC) (“Falco” or the “Corporation”) would like to thank all those who participated and enriched the discussions during the public information period of the Bureau d’audiences publiques sur l’environnement (BAPE) and reiterates its commitment to working closely with the community, environmental groups, and authorities for the success of Falco’s Horne 5 Project (“Falco’s Horne 5 Project” or the “Project”). This information period, which was held from April 24 to June 10, 2024, allowed citizens, groups, the municipality and organizations to learn about the various environmental, economic and social aspects of the Project. During this period, it was also possible to make requests for public consultation or mediation to...

Bird to Acquire B.C.-Based Civil Infrastructure Contractor for $135 Million, Expects Resulting 10% Full Year Adj. EPS Accretion

Written by Customer Service on June 10, 2024. Posted in Mergers And Acquisitions.

TRANSACTION HIGHLIGHTS Establishes Bird in BC’s high-demand civil infrastructure market and adds significant scale and diversification in the region. Expected to enhance Bird’s Adjusted EBITDA Margins through focus on complex, specialized projects and self-perform work. Supports value creation through anticipated 10% Adjusted EPS accretion with further potential upside from cross-selling opportunities and other synergies. Implied purchase multiple of 3.7x Jacob Bros’ projected full year 2024 Adjusted EBITDA based on an estimated purchase price of $135 million, exclusive of future synergies. MISSISSAUGA, Ontario, June 10, 2024 (GLOBE NEWSWIRE) — Bird Construction Inc. (TSX: BDT) (“Bird” or “the Company”) announced today that it has entered into a definitive share purchase agreement (the “Agreement”) under which Bird will acquire...

GENFIT: Historic Milestone Achieved with U.S. FDA Accelerated Approval of Ipsen’s Iqirvo® for Primary Biliary Cholangitis

Written by Customer Service on June 10, 2024. Posted in Public Companies.

Ipsen’s Iqirvo® (elafibranor) 80 mg tablets receives U.S. FDA accelerated approval as a first-in-class treatment for Primary Biliary Cholangitis (PBC) First-ever drug developed in-house by GENFIT to achieve U.S. FDA’s approval GENFIT is eligible to receive a €48.7 million milestone payment from Ipsen upon the first commercial sale of Iqirvo in the U.S., as well as tiered double-digit royalties of up to 20% Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), June 10, 2024 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the achievement of a historic corporate milestone: the U.S. Food and Drug Administration (FDA) accelerated approval of Iqirvo1 (elafibranor)2 80 mg tablets...

Tiber Ventures, Inc. (fka SeaChange International, Inc.) Announces Tender Offer for up to $6.2mm of Shares of its Common Stock

Written by Customer Service on June 10, 2024. Posted in Public Companies.

BOSTON, June 10, 2024 (GLOBE NEWSWIRE) — Tiber Ventures, Inc., formerly known as SeaChange International, Inc., (OTC: SEAC) (“Tiber Ventures”) today is announcing a modified “Dutch auction” tender offer to purchase with cash up to $6.16 million of shares of its common stock, at a price per share of not less than $6.75 and not more than $7.25. The complete terms of the tender offer are set forth in the Offer to Purchase and the related Letter of Transmittal, each dated today. The tender offer will expire one minute after 4:59 P.M. Eastern Daylight Time on July 10, 2024 unless extended by Tiber Ventures or otherwise terminated. Tenders of shares must be made on or prior to the expiration of the tender offer and may be withdrawn at any time prior to the expiration of the tender offer, in each case, in accordance...

Whitestone REIT Declares Third Quarter 2024 Dividend

Written by Customer Service on June 10, 2024. Posted in Dividend Reports And Estimates.

HOUSTON, June 10, 2024 (GLOBE NEWSWIRE) — Whitestone REIT (NYSE: WSR) (“Whitestone” or the “Company”) today announced that its Board of Trustees has declared a monthly cash dividend of $0.04125 per share on the Company’s common shares and operating partnership units for the third quarter of 2024. The dividend represents a quarterly amount of $0.12375 per share, and an annualized amount of $0.495 per share. The third quarter dividend distribution for 2024 will be as detailed below: Month Record Date Payment Date Distribution perShare/Unit July 7/5/2024 7/11/2024 $0.04125 August 8/2/2024 8/14/2024 $0.04125 September 9/4/2024 9/12/2024 $0.04125 About Whitestone REIT Whitestone REIT (NYSE: WSR) is a community-centered real estate investment trust (REIT) that acquires, owns, operates, and develops open-air,...

Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis

Written by Customer Service on June 10, 2024. Posted in Public Companies.

Iqirvo® (elafibranor) 80 mg tablets is the first new medicine approved in nearly a decade for the treatment of the rare liver disease called primary biliary cholangitis Approval based on positive Phase III ELATIVE trial data Primary biliary cholangitis impacts approximately 100,000 people in the US and is growing in global prevalence. If inadequately treated, it can cause liver failure U.S. approval of Iqirvo establishes Ipsen as a leader in the treatment of rare cholestatic liver diseases PARIS, FRANCE, 10 June 2024 Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Iqirvo® (elafibranor) 80 mg tablets for the treatment of primary biliary cholangitis (PBC) in combination with...

Vornado’s Retail JV Completes $400 Million Refinancing of 640 Fifth Avenue

Written by Customer Service on June 10, 2024. Posted in Public Companies.

NEW YORK, June 10, 2024 (GLOBE NEWSWIRE) — Vornado Realty Trust (NYSE:VNO) announced today that its 52% owned street retail joint venture has completed a $400 million refinancing of 640 Fifth Avenue, a 315,000 square foot Manhattan office and retail property. The interest only, non–recourse loan carries a fixed rate of 7.47% and matures in July 2029. The street retail joint venture paid down by $100 million the prior $500 million loan, which was fully guaranteed by Vornado, bore interest at SOFR plus 1.11% and was scheduled to mature in August 2024. Vornado Realty Trust is a fully-integrated equity real estate investment trust. CONTACT Thomas J. Sanelli(212) 894-7000 Certain statements contained herein may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking...

Day: June 10, 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice